From Farm to Feast: National Consumers League Says You Should be Concerned About Food Safety This Holiday Season

/in Featured Home - Food & Nutrition, Press release/by

Avoid foodborne illness this Thanksgiving with simple steps for safe thawing, cooking, and leftovers.  

Media Contact: Lisa McDonald, Vice President of Communications, 202-207-2829  

Washington, DC – As Thanksgiving and Christmas quickly approach, the National Consumers League (NCL) reminds consumers that foodborne illnesses are on the rise. Still, some simple food safety practices will keep holiday meals safe and enjoyable for family and friends.  

“Food safety during the holidays should be a priority,” said NCL Director of Food and Nutrition Policy, Nancy Glick. “Foodborne illnesses affect about 48 million Americans annually, but spike over the holiday season when larger gatherings and leaving food out for extended periods create more opportunities for bacteria to grow and spread.”

Knowing how to prevent foodborne illness requires understanding what this health problem is, who is most at risk, and the types of foods that are most likely to become contaminated and harbor the bacteria that cause most cases of foodborne illness during the holidays.  

However, within these food categories, the USDA has identified a number of holiday foods that are known to carry food safety risks because they are more vulnerable to contamination.  These foods include stuffing made with raw poultry, stuffing, or casseroles, undercooked poultry (like turkey), raw eggs in dishes such as eggnog, and deli meats, especially if they are store-prepared deli salads. Other holiday foods that require attention are leafy greens, ready-to-cook dough and batter, raw or undercooked shellfish and especially oysters, and cooked rice left at room temperature, which can become breeding grounds for bacteria.   

Towards this end, information from the Centers for Disease Control and Prevention (CDC) is invaluable. Starting with a definition, CDC describes foodborne illnesses, also known as “food poisoning,” as diseases transmitted to people by eating or drinking something contaminated with bacteria, viruses, parasites, or chemicals, such as toxins or metals.  While a foodborne illness can be severe, leading to hospitalization, long-term health problems, and even death, most cases are mild and involve symptoms like upset stomach, diarrhea, and vomiting that resolve in a few days.   

The problem, however, is that certain groups of people are more susceptible to foodborne illness than others – meaning they are more likely to get sick from contaminated food. If they do get sick, the effects are often more serious. Thus, it is essential to be vigilant in following safe food-handling practices when shopping for, preparing, and storing foods that will be served to children under age 5, older adults, pregnant women, and people being treated for diabetes, cancer, autoimmune diseases, and HIV.   

The US Department of Agriculture (USDA) cautions consumers to be aware of holiday foods that can harbor bacteria like Salmonella, E. coli, and Listeria if not cooked or stored correctly. Using data reported from studying foodborne outbreak-related illnesses occurring between 1998 and 2008, USDA researchers determined that plant-based foods, including fruits, nuts, and vegetables, accounted for the most cases of foodborne illness (51 percent), followed by meat and poultry (42 percent) and dairy products (14 percent).      

Glick continues, “Knowing the risks associated with foodborne illness and the common holiday foods that may cause people to get sick are the keys to having a safe and healthy holiday. Foodborne illness is preventable, but this requires being serious about food safety practices, from handwashing, safe thawing methods, preventing cross-contamination, and keeping foods at safe temperatures.”

It’s not too early to brush up on safe food preparation and storage practices. As you gather with loved ones to celebrate the holidays, keep these practices in mind to help prevent foodborne illness.  

NCL’s Top Food Safety Tips for a Healthy Holiday  

  1. Thaw safely: Never Thaw a turkey on the counter. Defrost in the refrigerator (24 hours per 4–5 pounds) or in cold water, changing the water every 30 minutes. 
  2. Cook thoroughly: Use a food thermometer — turkey breast should reach 165°F, thighs 175°F. Don’t rely on color alone.  
  1. Avoid cross-contamination: Keep raw poultry separate from other foods. Wash your hands, utensils, and cutting boards often.  
  1. Handle leftovers with care: Refrigerate within two hours, store in shallow containers, and reheat to 165°F. Discard after 3–4 days.  

###  

About the National Consumers League (NCL)       

The National Consumers League, founded in 1899, is America’s pioneer consumer organization. Our mission is to protect and promote social and economic justice for consumers and workers in the United States and abroad. For more information, visit www.nclnet.org. 

The National Consumers League Applauds the Trump Administration For Lowering the Price of GLP-1 Weight Loss Drugs

/in Featured Home - Food & Nutrition, Featured Home - Your Health, Press release/by

Media Contact: Lisa McDonald, Vice President of Communications, 202-207-2829  

Washington, DC – On behalf of the estimated 100,000 million US adults with obesity, many of whom are seeking treatment with FDA-approved anti-obesity medicines, the National Consumers League (NCL) applauds the Trump Administration for negotiating lower prices for the popular GLP-1 (glucagon-like peptide-1) weight loss drugs, Wegovy© (semaglutide) and Zepbound© (tirzepatide), so these medicines are more accessible to those needing quality obesity care.

According to an agreement the White House reached with the manufacturers of Wegovy and Zepbound, as of mid-2026, the Medicare program will purchase injectable semaglutide and tirzepatide – and later the pill forms when approved by the FDA — at $149 per month for the lowest dose and $245 per month for larger doses. This means that Medicare will be able to cover GLP-1 weight loss drugs for the first time, with Medicare beneficiaries responsible for co-pay of just $50 per month. Moreover, state Medicaid programs will benefit from these discounts, thereby allowing more people with obesity to receive quality obesity care in the country.

Also of note, starting in January 2026, Americans not eligible for Medicare or Medicaid will be able to buy Wegovy and Zepbound directly from the government website, Trumprx.gov, for $350 or less per month. This represents a significant discount from the price the manufacturers currently offer to consumers through their direct-to-consumer online pharmacy programs.

Collectively, the actions by the Administration will improve the lives of millions of Americans with obesity, who for too long, have been denied access to medicines that are clinically effective in achieving significant weight loss.

However, NCL joins with other members of the obesity community in calling on Congress to pass the Treat and Reduce Obesity Act (TROA) this year. By enacting this legislation, Congress will ensure that Medicare beneficiaries have coverage for GLP-1 drugs. At the same time, TROA will expand access to intensive behavioral therapy (IBT) in more clinical settings, allowing more adult Americans to receive counseling that promotes sustained weight loss through high intensity interventions on diet and exercise.

###  

About the National Consumers League (NCL)       

The National Consumers League, founded in 1899, is America’s pioneer consumer organization. Our mission is to protect and promote social and economic justice for consumers and workers in the United States and abroad. For more information, visit www.nclnet.org.   

A War on the Hungry: NCL Denounces Federal Inaction on SNAP

/in Featured Home - Food & Nutrition/by

Media Contact: Lisa McDonald, Vice President of Communications, 202-207-2829

Washington, DC – The National Consumers League (NCL) is deeply alarmed by the federal government’s refusal to use billions in emergency funds to sustain the Supplemental Nutrition Assistance Program (SNAP). This reckless decision constitutes a direct assault on the nation’s most vulnerable—our children, the sick, the poor, the elderly, and the disabled—and risks plunging tens of millions back into hunger and hardship.

“Forcing millions of Americans to go hungry while sitting on billions in available funds is unconscionable,” said NCL CEO Sally Greenberg. “This is a war on the most defenseless members of our society, and history will not look kindly on those who turned their backs. Feeding the hungry is not a partisan issue—it is a moral imperative.”

NCL calls on the administration to immediately deploy the contingency funds intended to prevent hunger and protect the health and dignity of all Americans.

To learn more about the roots of America’s hunger crisis and what’s at stake, read NCL’s latest blog post, A Call Not to Make Americans Hungry Again, by Food and Nutrition Policy Director Nancy Glick.

###  

About the National Consumers League (NCL)        

The National Consumers League, founded in 1899, is America’s pioneer consumer organization. Our mission is to protect and promote social and economic justice for consumers and workers in the United States and abroad. For more information, visit www.nclnet.org.    

Nancy Glick

A Call Not to Make Americans Hungry Again

/in Featured Home - Food & Nutrition, Thought Leadership/by

By Nancy Glick, Director of Food and Nutrition Policy

1968 was a pivotal year in U.S. history, and not only for the anti-war protests and the assassinations of Martin Luther King Jr. and Robert F. Kennedy. That same year, CBS News aired “Hunger in America,” a Peabody-winning documentary that opened the eyes of Americans to the fact that over 10 million people – nearly 20 percent of the public – were suffering from hunger and malnutrition in a land of plenty. 

Later that year, a group of 25 religious, labor, legal, medical, and other professionals, including the Citizens’ Board of Inquiry into Hunger and Malnutrition, published a scathing report documenting widespread hunger and malnutrition across the country. Called “Hunger U.S.A.,” the report identified 282 “hunger counties,” especially in areas like Appalachia, the Mississippi Delta, and Native American reservations, and described the dire conditions for people experiencing hunger,  made worse by federal programs that discriminated against the poor and favored agricultural companies.  

The report and the documentary shocked the nation, prompting significant public and political pressure that led President Richard Nixon to convene the first-ever White House Conference on Food, Nutrition, and Health in Washington in December 1969. Attended by 5,000 delegates representing various interest groups, the conference produced more than 1,800 recommendations to improve anti-hunger programs. The conference was also the stimulus for Congress to pass landmark legislation – such as the 1974 Food Stamp Act, the 1975 School Breakfast Program and Summer Food Program, and authorization of the Supplemental Feeding Program for Women, Infants, and Children (WIC) – that now make it possible for more low-income families to have a healthy diet.   

Fast-forward 56 years after the White House Conference , and the nation is staring at the possibility of another wave of massive hunger in America. Despite how much has changed over the last five decades, an estimated 47.4 million Americans now experience food insecurity, including over 13 million children. The consequences for malnourished people are wide-ranging. Adults experience more severe illnesses, disability, muscle wasting, and chronic diseases, while children may face stunted growth, developmental delays, learning difficulties, and reduced cognitive function. 

Given this reality, one would think that reducing hunger in America would be a priority for the White House and members of Congress. Yet, passage of the President’s One Bill Beautiful Bill Act (OBBBA) in July shows this is not the case. OBBBA cut $186 billion in funding for roughly one in eight people in the U.S. who buy groceries with help from the Supplemental Nutrition Assistance Program (SNAP), also known as the food stamp program. When the cuts take effect in 2027, the Urban Institute projects that 22.3 million families will lose some or all of their SNAP benefits. Additionally, the Congressional Budget Office (CBO) estimates that 3.2 million adults will be cut from the SNAP program in a typical month due to expiring exemptions. This includes 1 million older adults, 800,000 parents, and 1.4 million adults in areas with insufficient jobs.  

But now, nearly 42 million people could lose their SNAP benefits this year – as early as November 1. This reason is an ongoing fight in Congress over how to end a federal government shutdown, where food-insecure Americans are being used as pawns. Senate Republicans insist that Democrats vote to approve a “clean” budget spending bill with no changes. In contrast, Democrats want the bill to include an extension of expiring tax credits that will make health insurance cheaper for millions of Americans and to reverse Medicaid cuts.  

The haggling has been ongoing since October 1, when the government shut down, and efforts to reach a compromise have failed. Thus, the Trump Administration is using continued funding for SNAP benefits as a pressure tactic to raise the ante on Senate Democrats. This took the form of the USDA announcing on its website on October 26 that “the well has run dry,” and there will be no SNAP benefits issued on November 1. 

What the USDA didn’t say is that the department has access to a nearly $6 billion contingency fund that paid for SNAP benefits during past government shutdowns. Many Congressional Democrats and Republicans had encouraged the Trump administration to use this funding to preserve food stamps through November, as the government was expected to remain closed. But the Trump administration declined, even though USDA said weeks ago that it could reprogram money to prevent benefit cuts. 

People receiving SNAP benefits should not be used as a bargaining chip in a game of chicken between Republicans and Democrats. Therefore, Democratic attorneys general and governors from 25 states filed a lawsuit in federal court on October 28, arguing that the federal government had a legal obligation to maintain funding for food stamps, which Congress made permanent in the 1960s.  

Soon, we will know if the federal court sides with state attorneys general and governors and compels USDA to use its contingency fund so nutritionally vulnerable Americans will continue to have enough food. If not, over 40 million children and adults can only hope that cooler heads will prevail, that Democrats and Republicans will come to the negotiating table, that the shutdown will end, and that SNAP benefits will be restored.  

But no one should declare victory. This is a dark moment in our history. 

Nancy Glick

Reversing Progress on Obesity Care

/in Featured Home - Food & Nutrition, Thought Leadership/by

By Nancy Glick, Director of Food and Nutrition Policy

“One step forward, two steps back” describes situations where progress is hindered by setbacks. This accurately reflects the state of obesity care today. 

On the positive side, the disease that now affects more than 100 million adult Americans is finally getting recognition as a priority health issue. This is due to several important developments demonstrating the value of treating obesity as a serious chronic disease: 

There is widespread scientific consensus that obesity is a high-risk condition

Starting with the American Medical Association’s (AMA) action in 2013 to classify obesity as a serious chronic disease requiring treatment, numerous chronic diseases, obesity and nutrition organizations now agree that obesity is a distinct disease due to its complex biological mechanisms and its worsening effect on over 230 other chronic diseases. Based on this consensus, in 2024, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule to establish treatment of obesity as a medically necessary service under Medicare and Medicaid, paving the way for covering weight loss drug under these programs in the future.

New therapeutic agents are revolutionizing obesity medicine

When the Food and Drug Administration (FDA) approved the first GLP-1 (glucagon-like peptide-1 receptor) agonist to treat obesity in 2021, Americans learned that these injectable medicines could help people lose between 15 percent and 25 percent of their weight on average after one year. Thus, enthusiasm for GLP-1s has soared to levels rarely seen in medical practice. According to the findings of a 2024 survey of 3,000 adults commissioned by the professional services firm PWC, between 8 percent and 10 percent of US adults are currently taking GLP-1s. 

GLP-1 medicines are cost-effective 

In September, the Institute for Clinical and Economic Review (ICER) gave its highest cost-effectiveness rating to the widely prescribed weekly injectable GLP-1 weight loss drugs, semaglutide and tirzepatide, citing price reductions and studies showing cardiovascular benefits. Additionally, FDA recently approved the first generic version of an older GLP-1, liraglutide, which is injected daily. 

New research shows that treating obesity lowers overall healthcare costs

Because even a modest weight loss (a drop of 5-10 percent) produces significant health improvements when a person has overweight or obesity, studies are beginning to project the potential savings to the economy from covering obesity medications. One large study of privately insured adults and Medicare beneficiaries published December 5, 2024, in JAMA Network Open estimated an annual savings of $2,430 per person who achieved a 10 percent reduction in excess weight and a $5,444 reduction in health expenditures with a 25 percent weight loss.  

Reflecting these developments, coverage of GLP-1 drugs increased in 2023 and 2024, particularly among large employers. According to the firm Mercer, which conducts an annual National Survey of Employer-Sponsored Health Plans, coverage for GLP-1 drugs in 2024 rose to 44 percent of all large employers (those with 500 or more employees) and up to 64 percent of corporations with 20,000 or more employees.  

Additionally, the Office of Personnel Management (OPM) required Federal Employee Health Benefits (FEHB) carriers to cover at least one GLP-1 weight loss drug in 2024, and the Civilian Health and Medical Program of the Department of Veterans Affairs (CHAMPVA) covered these medicines for chronic weight management. At the same time, several states provided some level of GLP-1 coverage for their employee health plans and 13 state Medicaid programs covered GLP-1 weight loss drugs as of August 2024.  

But, as the saying goes, that was then, and this is now. Due to dramatic cuts in federal and state budgets, the nation is shifting course with the inevitable result of moving backwards in delivering quality obesity care. While not the complete picture, the National Consumers League notes these troubling reversals:

  • In April 2025, the Trump Administration announced that Medicare will not cover anti-obesity medications, stating that the 2024 CMS proposal to cover GLP-1 weight loss drugs “is not appropriate at this time.” 

If obesity were cancer or heart disease, policymakers might think twice about not allowing access to cost-effective medications. Yet, the reality is that obesity is still not viewed as a serious disease. Thus, obesity remains largely undertreated in this country, due in part to payers, federal agencies, and state governments restricting or eliminating coverage for anti-obesity medicines that are changing the standard of care.  

Recognizing that people with obesity deserve the same level of attention and care as those with other chronic diseases, the National Consumers League partnered with the National Council on Aging (NCOA) and leading obesity specialists to develop and issue the first Obesity Bill of Rights for the nation on January 31, 2024. Specifically, the Obesity Bill of Rights defines quality obesity care as the right of all adults and establishes eight essential rights, including the right to coverage for the full range of treatment options, ensuring that Americans with obesity recieve the care specified in medical guidelines. 

To ensure Americans have these rights, NCL and obesity advocates are urging policymakers to adopt a long-term view about the importance of covering anti-obesity medications. Our message is simple: there may be short-term budget savings from restricting or eliminating coverage, but if obesity goes untreated among a large segment of the population, the nation will pay the costs in higher annual expenditures on obesity-related chronic diseases, disability, lost productivity, and premature deaths.  

Complicating matters, not having insurance coverage is what drives many consumers to go online and opt for ‘cheap, easy, and doctor-approved’ compounded GLP-1 products that may cause harm or could be fakes. According to the Food and Drug Administration, these products may contain incorrect dosages, the wrong ingredients, excessive or insufficient amounts of active ingredients, or possibly bacteria, all of which can lead to serious health consequences. Thus, while several medical organizations and state attorneys general have issued alerts to warn consumers, advocates agree that providing coverage for FDA-approved GLP-1 drugs is the best way to put a damper on this exploitative market.  

For all these reasons, NCL urges insurers and federal and state policymakers to consider the significant health and patient safety benefits, as well as the reduced medical expenditures from treating obesity, when weighing decisions about coverage.  

Consumer, Patient Safety, and Public Health Groups Petition the FTC to Stop the Deceptive Online Marketing of Unapproved Weight Loss Drugs

/in Featured Home - Food & Nutrition, Press release/by

A National Consumers League Review Finds the Promotion by Several Online Telehealth Platforms Misleads the Public About the Safety of Compounded GLP-1 Products and Violates FTC’s Prohibition Against False and Deceptive Advertising

Media Contact: Lisa McDonald, Vice President of Communications, 202-207-2829

Washington, DC, – Now that a Presidential memorandum directs the Food and Drug Administration (FDA) to ensure accuracy in direct-to-consumer prescription drug advertising and the September 9 MAHA Report calls on the Federal Trade Commission (FTC) to apply its existing authorities to DTC telehealth companies, the National Consumers League (NCL) and 12 patient safety, pharmacy, women’s health and minority health organizations have submitted a petition asking the FTC to launch an investigation of the deceptive marketing practices of telehealth platforms promoting weight loss drugs.

Reinforcing the July 17, 2025, letter to the FTC from Senator Marsha Blackburn (R-TN), urging a probe of the questionable online marketing surrounding GLP-1 agonists, the petition provides a roadmap for the FTC to investigate the direct-to-consumer advertising practices of telehealth platforms that promote compounded GLP-1 drugs through tactics that violate the FTC’s prohibition against false and deceptive advertising. These practices include ads that expose consumers to unsubstantiated claims and misleading inferences regarding the comparable safety, efficacy, and ingredients used in compounded GLP-1 products. As described in the petition, there has been a 1200 percent increase in “violative or problematic” GLP-1 related ads since 2022, resulting in an alarming amount of misleading information that causes consumer confusion, leads to risk-taking behaviors, and perpetuates fraud.

“Compounded GLP-1s are not the same as FDA-approved medications – and not knowing the differences puts American consumers at risk,” said Sally Greenberg, CEO of the National Consumers League (NCL). “The FTC must act swiftly to stop deceptive advertising and protect consumers from potentially serious health problems associated with compounded GLP-1 drugs.”

Based on an in-depth analysis NCL conducted in April 2025 of the headings, claims, omissions of fact, and use of visuals and hyperlinks contained in widely disseminated TV and digital ads promoting compounded GLP-1 drugs, these practices fall into three categories that violate the Federal Trade Commission Act: 1) ads that omit  “material risk information,” such as side effects and contraindications, 2) content that contains statements and omissions that would mislead a reasonable consumer regarding FDA approval, and 3) unsubstantiated claims regarding product safety and efficacy. Some examples include:

  • Broadcast and digital ads that completely omit all risk and safety information about compounded GLP-1 products
  • Ads that only include brief, superimposed risk declaimers stating that GLP-1 drugs “may differ in risks, benefits, and side effects”
  • Putting risk disclosure information in small, hard-to-read type and flashing it quickly in TV spots
  • Making implied claims of FDA approval and/or the sameness with the branded drug by juxtaposing images of compounded drugs with easily recognized FDA-approved products, or stating that the compounded version has the “same active ingredient”
  • Using terms like “clinically backed weight loss treatment,” “doctor trusted,” and “trusted by experts” with no substantiation

The following organizations joined with the National Consumers League in submitting the petition: Aimed Alliance, American Medical Women’s Association, Association for Safe Online Pharmacies, Center for Medicine in the Public Interest, Health Equity Coalition on Chronic Disease, HealthyWomen, League of United Latin American Citizens, MANA, A National Latina Organization, National Asian Pacific Center on Aging, National Council on Aging, National Hispanic Council on Aging, and the Partnership for Safe Medicines.

Because deceptive advertising too often deceives consumers into believing that compounded GLP-1s are as safe as branded versions, only cheaper and easier to obtain online, the petition documents the harm in serious health problems related to dosing errors and reactions to harmful ingredients in compounded GLP-1 products. As of September 9, 2025, the FDA has received 1,424 reports of adverse events associated with compounded GLP-1 drugs, including reports of 329 hospitalizations and 23 deaths, while poison control centers have seen a nearly 1,500 percent increase in calls since 2019 due to overdose or side effects.

Additionally, patient safety advocates warn that many compounded GLP-1s use active pharmaceutical ingredients (API) sourced from China, where quality standards vary and APIs may go uninspected. Further, the petition points to new health risks for consumers as compounders and telehealth companies pivot to promoting “personalized” versions of GLP-1s with added vitamins or microdoses of GLP-1s that have never been studied.

“When drug compounders use added substances or altered dosages to evade restrictions on copying FDA-approved medications, they endanger consumers by dispensing products that have not been proven safe or effective for their intended uses,” said Michael C. Barnes, counsel to Aimed Alliance. “By promoting and selling drugs that have not undergone rigorous clinical trials and FDA review, compounders also erode the integrity of the U.S. drug approval and marketing system.”

While deceptive advertising of compounded GLP-1 drugs is a national problem that perpetuates fraud, advocates are especially concerned about the influence of highly deceptive ads on women, the primary users of GLP-1 drugs, including girls 14 years and younger who are increasingly motivated to take microdoses of a GLP-1 drug to control their weight.  However, those at greatest risk of harm are women of color, who the data show tend to be more susceptible to scams offering cheaper, potentially fraudulent or counterfeit alternatives online, through bodegas or illegitimate channels.

Additionally, the League of United Latin American Citizens (LULAC) asserts that Latinas are especially vulnerable to deceptive Spanish language ads on television, radio, and social media, as well as through informal networks – community centers, neighborhood bodegas, and Spanish language Facebook groups – where oversight is nonexistent.

“This is a worst-case scenario for the Latina community,” said Ray Romano, LULAC’s Director of Research and Policy. “For many Latinas, especially those with limited English proficiency, these ads may be their only source of information about compounded GLP-1 drugs. Latina patients are also desperate for affordable treatment, which is why this exploitative marketing creates an especially dangerous pipeline for fraud and harm.”

Study Methodology
Months in development, the petition draws on research on telehealth marketing of compounded GLP-1 products, including a content analysis conducted by the NCL of the headings, subheads, claims, omissions, and the placement of visuals in television and digital ads widely disseminated online in the first half of 2025. The petition also incorporates input from stakeholders focused on patient safety, consumer fraud, and populations especially vulnerable to online misinformation.

The full petition can be found here.

 ###

About the National Consumers League

The National Consumers League, founded in 1899, is America’s pioneer consumer organization. The organization’s mission is to protect and promote social and economic justice for consumers and workers in the United States and abroad. For more information, visit www.nclnet.org.

Crackdown on Deceptive Weight Loss Drug Ads Marks Victory for Consumers

/in Featured Home - Food & Nutrition, Press release, Press releases, health/by

Media Contact: Lisa McDonald, Vice President of Communications, 202-207-2829 

Washington, DC – Justice delayed was justice denied to millions of Americans who have been exposed to a flood of deceptive advertising about the safety of the same weight loss drugs that the Food and Drug Administration warns are not approved and “could be risky for patients.”  Now, FDA is standing up for consumers by sending 100 cease-and-desist letters that tell online sellers of compounded GLP-1 drugs that it is a breach of FDA regulation to tout the benefits of the weight-loss drugs without any mention of side effects and to stop this “false or misleading” marketing.  

“Americans need a cop on the beat to protect them from the rampant disinformation now circulating online that causes consumers to tune out the advice of the FDA and leading medical societies and opt for drugs that may cause harm or could be fakes, says Nancy Glick, Director of Food and Nutrition Policy. The National Consumers League welcomes FDA’s commitment to monitor the content and claims of companies promoting GLP-1 weight loss medicines and other prescription drugs and to enforce prescription drug advertising regulations aggressively. 

### 

About the National Consumers League (NCL)      

The National Consumers League, founded in 1899, is America’s pioneer consumer organization. Our mission is to protect and promote social and economic justice for consumers and workers in the United States and abroad. For more information, visit www.nclnet.org.    

Fraud, Counterfeits, and Unsafe Doses: NCL Sounds Alarm on Compounded GLP-1 Market

/in Featured Home - Food & Nutrition, Press release/by

 Media Contact: Lisa McDonald, Vice President of Communications, 202-207-2829 

Washington, DC –  On behalf of the millions of consumers who have been lulled into believing that compounded GLP-1s are safe and effective for weight loss, the National Consumers League (NCL) appreciates the Food and Drug Administration’s updated policy statement warning that these drugs can carry significant health risks and should only be taken by patients who cannot tolerate the widely available FDA-approved GLP-1 medicines. 

Specifically, the FDA’s statement makes clear that: 

Compounded GLP-1s are unapproved products that do not undergo the FDA’s review for safety, effectiveness, and quality before they are marketed.  

Compounded GLP-1s carry significant safety risks and may cause serious adverse events, hospitalizations, and in some cases death. These adverse events are directly linked to dosing errors when patients measure and self-administer incorrect doses of the drug, and in some cases, when health care professionals miscalculate doses of the drug.  

The FDA has received 1,150 reports of adverse events related to compounded versions of semaglutide and tirzepatide as of July 31, 2025. Because federal law does not require all compounders to submit adverse reaction reports, these numbers are the tip of the iceberg in terms of harm to consumers. 

The FDA is aware of fraudulent compounded semaglutide and tirzepatide marketed in the U.S. that contain false information on the product label.  

The FDA is also aware that counterfeit GLP-1s are widely available online and may contain the wrong ingredients, contain too little, too much, or no active ingredient at all, or other harmful ingredients, and are illegal.  

Similarly, the agency is warning the public that bad actors are illegally selling directly to consumers unapproved ingredients falsely labeled “for research purposes” or “not for human consumption,” which are extremely dangerous. 

Making these concerns known is necessary to protect the public, but the National Consumers League calls on the FDA to take the next step by issuing regulations that will actually solve these problems and keep Americans safe. 

Unless the FDA acts forcefully, the tide of misleading online marketing of compounded GLP-1 drugs will continue, and the public will be faced with a “caveat emptor” approach that requires patients to fend for themselves. As a consequence, consumers will continue to choose treatments that may increase their health risks or opt for fraudulent and counterfeit drugs, including dangerous products that are falsely labeled “for research purposes” or “not for human consumption.” 

### 

About the National Consumers League (NCL)      

The National Consumers League, founded in 1899, is America’s pioneer consumer organization. Our mission is to protect and promote social and economic justice for consumers and workers in the United States and abroad. For more information, visit www.nclnet.org.    

CDC Guts Food Safety Net: A Dangerous Gamble with American Lives

/in Featured Home - Food & Nutrition, Press release/by

Media Contact: Lisa McDonald, Vice President of Communications, 202-207-2829 

Washington, DC – In 1736, Benjamin Franklin advised the people of Philadelphia that “an ounce of prevention is worth a pound of cure.” Our famous forefather was talking about fire prevention but his words should now be directed to the Centers for Disease Control and Prevention (CDC), which recently cut its Food Diseases Active Surveillance Network (FoodNet) to track only infections from two foodborne pathogens, Salmonella and Shiga toxin–producing Escherichia coli (STEC).  

It is true that Salmonella and STET are among the top contributors to foodborne illnesses in the U.S. Yet, another six major pathogens – Campylobacter, Cyclospora, Listeria, Shigella, Vibrio, and Yersinia –also contribute to the estimated 48 million cases of foodborne illness in the US every year. And now, CDC has decided that it will be up to the states participating in FoodNet to determine if and how they will track and report illnesses from these pathogens.

It is worth remembering that the CDC created FoodNet in 1995 as a response to the 1992–1993 Jack in the Box E. coli outbreak, when over 700 people were badly sickened and four children died from eating hamburgers containing the deadly strain of Escherichia coli O157:H7 bacterium. It was a national scandal the country vowed not to repeat. “Sadly, the CDC has decided to play Russian Roulette with the health of Americans because states simply do not have the ability to coordinate information and data beyond their borders,” says Nancy Glick, Director of Food and Nutrition Policy at the National Consumers League. Therefore, the detection and information-sharing about major food pathogens will become more difficult and the spread of foodborne disease outbreaks will be more likely.

### 

About the National Consumers League (NCL)      

The National Consumers League, founded in 1899, is America’s pioneer consumer organization. Our mission is to protect and promote social and economic justice for consumers and workers in the United States and abroad. For more information, visit www.nclnet.org.    

The National Consumers League Applauds the Reintroduction of the Treat and Reduce Obesity Act; Urges Swift Action

/in Featured Home - Consumer Protection, Featured Home - Food & Nutrition, Featured Home - Your Health/by

Media Contact: Lisa McDonald, Vice President of Communications, 202-207-2829 

Washington, DC – Months after the Centers for Medicare and Medicaid Services (CMS) determined in a proposed rule that Medicare Part D should cover anti-obesity medications as a “medically necessary” service for people with the disease of obesity, the National Consumers League today applauded the reintroduction of the Treat and Reduce Obesity Act (TROA) in the 119th Congress as a critical step towards realizing this goal.  

Introduced in the Senate by Senators Bill Cassidy (R-LA) and Ben Ray Lujan (D-NM), TROA aims to advance obesity care for older Americans by expanding access to intensive behavioral therapy (IBT) beyond the primary care setting and by allowing Medicare Part D to cover FDA approved anti-obesity medications (AOMs), including new injectable drugs called GLP-1s (glucagon-like peptide-1 receptor agonists). As such, TROA’s passage would end discriminatory and out-of-date Medicare policies and remove one of the biggest obstacles impeding access to quality obesity care by ensuring Medicare beneficiaries with obesity will have the same access to GLP-1s as those prescribed these drugs for treatment of type 2 diabetes and cardiovascular disease.  

When TROA was first introduced during the 113th Congress in 2013, 37.7 percent of adult Americans, or one in three adults, were living with obesity, and the American Medical Association responded by officially recognizing obesity as a serious disease requiring treatment. Now, obesity affects 41.9 percent of US adults  – more than 100 million people – which makes obesity the most prevalent chronic disease affecting Americans, significantly eclipsing the other most prevalent chronic diseases: heart disease, diabetes, chronic kidney disease, cancer, chronic lung disease, Alzheimer’s Disease, and stroke. Even more significantly, more than 230 medical conditions are directly linked to overweight and obesity, meaning these diseases worsen as the degree of obesity increases. Thus, obesity today is responsible for an estimated 400,000 deaths a year and costs the US economy an estimated $1.72 trillion annually. 

Also of note, the science of obesity treatment has changed significantly since the Medicare Part D program went into effect in 2006, resulting in new therapeutic agents, such as GLP-1 drugs, that can help people lose up to 20 percent of their weight in 26 months. Calculating the potential savings resulting from better health outcomes when obesity is treated, studies are beginning to project the potential savings to the economy from covering obesity medications. One recent study published December 5, 2024, in JAMA Network Open, estimated that a 10 percent weight loss resulting from obesity treatment saved $2,430 in reduced medical expenditures, and for a 25 percent weight loss, the reduction in health expenditures is $5,444 per person.  

Besides these reasons, the National Consumers League welcomes the reintroduction of TROA as a way that Congress can drive nationwide adoption of the Obesity Bill of Rights, issued by NCL and the National Council on Aging (NCOA) in 2024. The Obesity Bill of Rights defines quality obesity care as the right of all adults and establishes eight essential rights, including the right for older adults to receive quality obesity care and the right to coverage for the full range of treatment options so Americans with obesity will get the care specified in medical guidelines.  

Accordingly, NCL looks forward to working with Senators Cassidy and Lujan to build support for TROA and to working with the sponsors of the companion House bill, which will be introduced soon. At a time when so much is at stake for the health of older adults, TROA can be a catalyst for Congress to help older adults realize these rights and improve the standard of care for millions of Americans with obesity.  

### 

About the National Consumers League (NCL)      

The National Consumers League, founded in 1899, is America’s pioneer consumer organization. Our mission is to protect and promote social and economic justice for consumers and workers in the United States and abroad. For more information, visit www.nclnet.org.